In NSCLC patients, RASi improved survival in carboplatin/paclitaxel-treated patients, but not when bevacizumab (anti-VEGF) was included, suggesting overlapping anti-angiogenic effects of bevacizumab and RASi [100]. Here, MMP19 is linked to non-small cell lung carcinoma.